Acadian Asset Management LLC Grows Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Acadian Asset Management LLC raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2,148.9% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 37,310 shares of the biopharmaceutical company's stock after buying an additional 35,651 shares during the quarter. Acadian Asset Management LLC's holdings in Alnylam Pharmaceuticals were worth $9,062,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Allspring Global Investments Holdings LLC grew its stake in shares of Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 143 shares during the last quarter. Altitude Crest Partners Inc. acquired a new position in Alnylam Pharmaceuticals during the 1st quarter valued at approximately $30,000. Robeco Institutional Asset Management B.V. raised its holdings in shares of Alnylam Pharmaceuticals by 155.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 12,513 shares during the last quarter. V Square Quantitative Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $52,000. Finally, Prestige Wealth Management Group LLC grew its holdings in shares of Alnylam Pharmaceuticals by 69.8% during the first quarter. Prestige Wealth Management Group LLC now owns 472 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 194 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ALNY. UBS Group lifted their price target on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a "buy" rating in a research report on Friday, June 28th. Royal Bank of Canada reiterated an "outperform" rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 4th. Stifel Nicolaus increased their price target on shares of Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a "buy" rating in a report on Thursday, June 27th. Wells Fargo & Company lifted their price objective on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an "equal weight" rating in a research note on Friday, August 2nd. Finally, JPMorgan Chase & Co. increased their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a "neutral" rating in a research note on Monday, August 26th. Seven investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $279.14.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY traded up $5.70 during mid-day trading on Wednesday, hitting $261.91. 652,238 shares of the company were exchanged, compared to its average volume of 899,654. The stock has a market cap of $33.62 billion, a price-to-earnings ratio of -97.73 and a beta of 0.38. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $287.55. The company has a 50 day moving average of $257.99 and a 200-day moving average of $193.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. During the same period in the previous year, the company earned ($2.21) EPS. Alnylam Pharmaceuticals's revenue was up 107.0% compared to the same quarter last year. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.78 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the transaction, the chief executive officer now directly owns 73,441 shares of the company's stock, valued at approximately $20,563,480. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CMO Pushkal Garg sold 2,103 shares of the business's stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $485,771.97. Following the transaction, the chief marketing officer now directly owns 15,609 shares in the company, valued at approximately $3,605,522.91. The disclosure for this sale can be found here. Insiders sold 103,148 shares of company stock valued at $25,658,824 over the last 90 days. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.